Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles;.
Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, USA.
Ann Oncol. 2017 Nov 1;28(11):2658-2669. doi: 10.1093/annonc/mdx348.
Chemotherapy has been explored as a treatment option for metastatic prostate cancer since the early 1980s. Docetaxel, a taxane chemotherapeutic, was approved for the treatment of men with metastatic castration-resistant prostate cancer in 2004, and is now standard of care for late stage disease. Recent clinical studies demonstrated that patients with metastatic castration-sensitive disease, and possibly those with high-risk localized prostate cancer also benefit from docetaxel administration, expanding the role of chemotherapy in the prostate cancer treatment landscape. Another taxane, cabazitaxel, is approved for post-docetaxel metastatic castration-resistant prostate cancer. Taxanes and other chemotherapeutics, such as carboplatin, are now being tested in combination regimens. This review presents an outline of recent and ongoing clinical studies assessing docetaxel and its derivative cabazitaxel at different stages of the disease, and in various combinations with other agents. We summarize current knowledge on biomarkers predictive of response to chemotherapy, which may in future be used to guide individualized treatment decisions.
自 20 世纪 80 年代初以来，化疗一直被探索作为转移性前列腺癌的一种治疗选择。多西他赛是一种紫杉烷类化疗药物，于 2004 年被批准用于治疗转移性去势抵抗性前列腺癌患者，现已成为晚期疾病的标准治疗方法。最近的临床研究表明，转移性去势敏感性疾病患者，可能还有那些高危局限性前列腺癌患者，也从多西他赛治疗中获益，扩大了化疗在前列腺癌治疗领域的作用。另一种紫杉烷类药物卡巴他赛也被批准用于多西他赛后转移性去势抵抗性前列腺癌。紫杉烷类药物和其他化疗药物，如卡铂，目前正在联合治疗方案中进行测试。这篇综述介绍了最近和正在进行的临床研究，评估了在疾病的不同阶段，以及与其他药物的不同联合方案中，多西他赛及其衍生物卡巴他赛的作用。我们总结了目前关于预测化疗反应的生物标志物的知识，这些标志物未来可能被用于指导个体化治疗决策。
